Welcome to our dedicated page for Cardiff Lexingto news (Ticker: CDIX), a resource for investors and traders seeking the latest updates and insights on Cardiff Lexingto stock.
Cardiff Lexingto (CDIX) operates as a diversified holding company specializing in strategic acquisitions of niche businesses, with a strong focus on healthcare markets. This page serves as the definitive source for official press releases, financial updates, and operational developments related to the company’s unique equity exit strategy model.
Investors and analysts will find timely information about CDIX’s portfolio growth, including acquisitions in orthopedic care through its Nova Ortho and Spine subsidiary. The curated news collection provides insights into capital allocation strategies, risk management practices, and compliance updates essential for evaluating this public holding company’s performance.
Content spans earnings announcements, partnership developments, regulatory filings, and market expansion initiatives. Regular updates reflect CDIX’s commitment to maintaining independent subsidiary management while leveraging public company resources – a dual approach central to its investment philosophy.
Bookmark this page for structured access to Cardiff Lexingto’s evolving business narrative. Check back frequently for verified updates that matter to stakeholders in healthcare investments and alternative exit strategy markets.
Cardiff Lexington Corporation (OTC PINK:CDIX) reported its 3rd quarter financial results for the period ending September 30, 2022. Key highlights include:
- Stockholders' Equity: Increased by 131%, totaling $6.4 million.
- Total Assets: Rose by 43%, reaching $15.9 million.
- Revenue: Grew by 47%, amounting to $9.4 million.
- Gross Margin: Up by 43%, totaling $6 million.
- Net Loss: Decreased by $1.9 million to ($813,054).
Management expressed optimism about moving beyond cash flow survival.
FAQ
What is the current stock price of Cardiff Lexingto (CDIX)?
What is the market cap of Cardiff Lexingto (CDIX)?
